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Abstract
In recent years, botulinum toxin and derma fi llers have made their way into dentistry 
for both dental esthetic and therapeutic uses. They are here to stay and with more and 
more intra oral uses of these materials, they are fast becoming an integral part of everyday 
dental practice. They provide most signifi cant, minimally invasive procedure at low cost 
with limited to no recovery time. Today botox and derma fi llers both go hand in hand for 
rejuvenative and cosmetic procedures. This article focuses on the mechanism of action 
and various uses of botox and derma fi llers in the maxillofacial areas along with its future 
implications in the dentistry.
Keywords: Botulinum toxin, dental esthetic, derma fi llers
Introduction
People face variety of dental issues during their life few of which 
includes stained, separated carious teeth along with various 
degree of irregular gum problems. This could act as a major 
downside in one’s look. An excellent smile can often be spoiled 
by irregular gum levels or excess gum. The cosmetic dentists will 
play a positive role in rectifying one’s gum connected problem 
and enhance the charm of one’s smile.
The gum is that part of the mouth which will have an eﬀ ect on 
one’s smile both health wise and cosmetically. If someone suﬀ ers 
from receding gums, his teeth seem longer and therefore the 
person appears older than he really is. Irregular gums can turn 
childlike smile into a criminal one. Use of botulinum toxin A 
(BTX) and dermal fi llers are gaining popularity for the treatment 
of irregular gums.
The popularity of each, BTX and dermal fi llers has matured 
quickly in recent years as a result of they provide the rejuvenative 
and enhancing aesthetic enhancements antecedently solely do 
able with surgery, however at lower value and with limited-to-no 
recovery time.
The use of neurotoxin and dermal fi llers is one in all the 
quickest growing areas of medical specialty. Esthetic results 
delivered in terms of smoothing wrinkles and commutation lost 
volume within the face, particularly the oral and peri-oral areas 
are very well known.
Botox in Dental Practice
BTX is a neurotoxin produced by the bacterium Clostridium 
botulinum. BTX that leads to botulism, a serious life-threatening 
illness in humans and animals that can even cause morbidity. 
Three forms of BTX type A (botox, dysport and xeomin) and 
one form of BTX type B (MyoBloc) are available commercially 
for various cosmetic and medical procedures.[1] BTX are being 
frequently used for dental esthetics, therapeutics along with 
treatment of temporomandibular joint syndrome and facial pain 
in faciomaxillary areas.
Mechanism of Action of Botulinum
The release of acetyl choline at the neuromuscular junction 
is inhibited by the toxin hence there is reduced intensity of 
contraction or complete elimination of overall contraction of 
the muscle, depending on the amount of toxin used [Figure 1]. 
Essentially, the neurotoxin interrupts the contraction process 
of the muscles and causes temporary muscle paralysis. This 
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can usually last up to 3 months as the muscle initiates new 
acetylcholine receptors and the growth of branches from the 
neurons to form new synaptic contacts. Slowly and steadily the 
muscle returns to its full function and with no side-eﬀ ects.[1]
Botox Dental Therapeutic Uses
1. Temporomandibular disorders (TMD) cases
2. Bruxism and clenching cases
3. Facial pain cases including treating trigger points
4. Treatment of angular cheilitis
5. Gummy smiles
6. Orthodontic relapse and depressed orthodontic appearance
7. Reducing muscle hyperactivity for retention of removable 
prosthodontics
8. Sialorrhea
9. Oromandibular dystonia
10. Trigeminal neuralgia.
TMD and facial pain
One or more trigger points in muscles are generally present in 
TMD cases. Palpating these points instantly causes transmission 
of pain along muscle or neuronal tracks emerging from these 
trigger points. Agents including sterile saline and local anesthetic 
have been used and injected directly into these trigger points. 
Disruption of the trigger point may bring relief, either short-term 
or long-term. As the eﬀ ect of sterile saline or local anesthetic lasts 
from a few minutes to only a few days the treatment benefi ts 
are limited. The use of BTX for these trigger points has been 
extremely benefi cial, the strength of the contraction of the 
muscle is reduced with the eﬀ ect lasting for 3 months.
Neurotoxins can be generally applied to various muscles 
of the face and mastication, including the trapezius, depressor 
anguli oris, sternocleidomastoid, splenius capitus, frontalis, 
procerus, corrugator, orbicularis oris, orbicularis oculi, masseter, 
temporalis mentalis, and pterygoid muscles for the TMD and 
facial pain cases.[2] The masseter and temporalis muscles are 
always treated bilaterally even if only one side of the face is 
involved.
Bruxism and masseteric hypertrophy
Bruxism is the general term that refers to both clenching and 
grinding of the teeth. It leads to the destruction of healthy dentition 
along with exacerbation of the periodontal disease, causing TMD, 
headaches and facial pain. Bilateral injections of toxin are given 
into the masseter and temporalis muscles in bruxism and TMD 
patients. Injecting the right amount will decrease the power of 
contractions of the muscles of mastication in addition to, improve 
ability for mastication and talking. The neurotoxins can help 
reduce facial pain, TMD symptoms and remove bruxism element 
thus in a way helping in treatment of periodontal diseases. 
Masseteric hypertrophy refers to enlargement of the masseter 
muscles. This often leads to clenching and bruxism. Treatment 
for masseteric hypertrophy is toxin being injected into the belly 
of the masseter muscle.[3] This will cause reduced intensity of 
contractions of the masseter muscles along with slenderization of 
face and like all other botulinium treatments, repeat injections are 
required every few months.
Orthodontic therapy
Relapse has been a continual problem for many general and 
orthodontic dental practitioners as teeth may continue to shift 
well after orthodontic therapy is complete. Many patients have a 
hyperactive mentalis muscle that often disrupts the alignment of 
teeth and may cause muscles to spasm. However, BTX can reduce 
muscle contraction intensity, allowing muscles to be retained to 
work properly over time. This could revolutionize how we deal 
with orthodontic relapse as more dental practitioners become 
familiar with botulinium uses.[4]
Removable prosthodontics
Increasing numbers of patients are receiving implant treatment 
to help stabilize their dentures, there will always be patients who 
either cannot aﬀ ord implant therapy or are not suitable candidates 
for the therapy. Many of these patients have hyperactive muscles, 
making it diﬃ  cult a to retain dentures in their mouths. Muscle 
training with the help of BTX may provide relief in these cases.
Sialorrhea
Excessive saliva production or the inability to hold saliva in 
the mouth can result in sialorrhea, more commonly known 
as drooling. Sialorrhea treatments include behavioral or 
occupational therapy and pharmaceutical treatments like 
scopolamine. However, also BTX can be used to treat sialorrhea 
via injection into the parotid and sub maxillary salivary glands, 
which inhibits the stimulation of the cholinergic receptor. This 
use of BTX to treat sialorrhea does not treat any muscles, but it 
does result in saliva reduction. However, this treatment must be 
Figure 1: Botulinium toxin blocks pre synaptic receptor and 
prevents release of acetylcholine 
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done carefully as too much neurotoxin can result in mastication 
diﬃ  culties, inability to swallow and dry mouth.
Oromandibular dystonia
It is a muscle dysfunction and pathology that involves the 
masticatory and lower facial muscles. It leads to unintended 
opening and closing of the mouth in vertical, lateral, and 
protrusive directions. This condition often results in involuntarily 
chewing of the soft tissue inside the mouth and also can interfere 
with regular chewing and speaking. Masseter injections of BTX 
have been reported to resolve some of these muscle dysfunctions.
Trigeminal neuralgia
Trigeminal neuralgia can be described as a sharp lancinating 
unilateral facial pain disorder that are generally limited to the 
distribution of one or more divisions of the trigeminal nerve. 
BTX is gaining popularity in its use regarding trigeminal neuralgia 
cases, it has been a very useful adjunct in treating these patients 
as primary or secondary treatment.[5] Adding botulinium to 
the treatment plan may result in signifi cant relief of trigeminal 
neuralgia symptoms.
Derma Fillers in Future Dental Practice
Derma fi llers are materials that are injected beneath the skin to 
add volume, smoothing out perioral folds and area of reduced 
volume. The perfect dermal fi ller would be cheap, safe, painless 
to inject, hypoallergic, and long lasting. In addition, it should 
have reliable and dependable results, feel natural beneath the 
skin, require very little time to inject, be ready-to use and have a 
low risk of complications. As the people become more aware 
about cosmetic treatments their demand to achieve a more 
younger look is increasing day by day, the cosmetic market has 
responded by providing the esthetic surgeons and dentists with 
an numerous options to meet the demands of the these type of 
patient.
Types of Derma Fillers
Dermal fi ller can be categorized as:
A. Biodegradable (moderate and long duration)
B. Non-biodegradable fi llers.
Moderate duration biodegradable fi llers
Example are collagen and the hyaluronic acid (HA) fi llers, they 
are reabsorbed by the body quite quickly, so their cosmetic 
benefi ts are fairly short-lived.
HA
HA is the most prominent glycosaminoglycan in the skin. It 
potently binds to water and, when injected into the skin, softens, 
volumizes and hydrates the skin. It plays important role in cell 
growth, membrane receptor function, and adhesion.
HAs are linear polymeric dimers of N-acetyl glucosamine 
and glucuronic acid,[6,7] there eﬀ ect lasts up to 6-18 months 
depending on the source, extent of cross-linking, concentration 
and particle size of each product.[8] To resist degradation by 
hyaluronidase, the crosslinking and the concentration of the HA 
is increased which in turn increase its viscosity and elasticity.
HA products are classifi ed by the size of their microspheres.
1. Example of biphasic fi llers are restylane, perlane, and 
macrolane contain diﬀ erent size of microsphere
2. Examples of monophasic HA products, such as juvederm, 
belotero, teosyal, prevelle silk, and varioderm, contain 
homogeneous microspheres and are more preferred fi llers.
Collagen
Collagen is the major structural constituent of the skin. The 
fi rst FDA-approved dermal fi ller was bovine collagen and 
was used until 2010, after which it was no longer produced. 
A bioengineered human collagen was FDA approved in the year 
2003 for injection use. As this newer dermal fi ller had no bovine 
collagen, it did not require any pretreatment allergy testing.
Lidocaine containing dermafi llers approved by FDA are 
both the bovine collagen (zyderm I, zyderm II, and zyplast) and 
bioengineered human collagen dermal fi llers (cosmoderm I, 
cosmoderm II, and cosmoplast), they are least painful for the 
patient upon injection, and thus eliminate the use of topical 
anesthesia or nerve blocks.[9]
Fillers with biodegradable particles
They stimulate the body to produce its own collagen and 
have longer duration of eﬀ ect; example include calcium 
hydroxylapatite (CaHA; Radiesse; Merz Pharmaceuticals 
GmbH) and poly-L-lactic acid (PLLA; Sculptra; Valeant, West 
Laval, QC, Canada).
CaHA
They are synthetic CaHA microspheres suspended in a carrier 
gel, example is Radiesse, which was approved in 2006 by FDA 
for the treatment of facial wrinkles and folds and HIV-associated 
facial atrophy. In 2009 FDA approved it for cosmetic use in non-
HIV patients also. It is composed of 30% CaHA and 70% carrier 
gel.[10]
Injection provides immediate visual improvement with long-
term deposition of new collagen surrounding the microspheres, 
contributing to an average duration of eﬀ ect of about 
15 months.[11]
PLLA
PLLA is an artifi cial, biocompatible, biodegradable, 
immunologically inert peptide polymer that is believed to 
stimulate fi broblasts to produce more collagen, thus increasing 
facial volume. It provides soft tissue augmentation through 
stimulation of an infl ammatory tissue response with subsequent 
collagen deposition.[12]
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PLLA produces a gradual treatment eﬀ ect and some degree 
of correction with each session of treatment. Three injection 
session are required but once fi nal correction is achieved results 
last up to 2 years.
Non-biodegradable fi llers
They provoke a foreign body reaction that stimulates a 
fi broblastic deposition of collagen around the non-absorbable 
microspheres.[13] Examples are polymethylmethacrylate 
(PMMA; Artecoll, the polyacrylamide hydrogel aquamid, and 
silikon 1000, a medical-grade pure form of silicone.
PMMA
It consists of 80% bovine dermal collagen plus 20% PMMA 
microspheres. The microspheres encapsulated by a fi ne fi brous 
capsule are left after the collagen vehicle is degraded within 
1-3 months. Aquamid is a hydrophilic polyacrylamide gel 
made up of 97.5% sterile water bound to 2.5% cross-linked 
acrylamide polymer. The polymer gets integrated with soft 
tissue, fl uid exchange occurs constantly between the hydrogel 
and surrounding tissue.[14]
Silikon 1000 is injected in minute amounts using a 
microdroplet technique, the body deposits collagen around 
the silicone particles. As they are non-biodegradable, their 
complications are more and diﬃ  cult to treat.
Cosmetic Indication Of Derma Fillers
1. Filling of rhytides (e.g., glabellar frown lines, forehead 
furrows, crow’s feet, fi ne perioral rhytides, shallow scars) and 
folds
2. Acne scars and wrinkles
3. Correction of soft tissue loss due to disease or age
4. Used for volume replacement and enhancement procedures, 
including:-
A. Cheek and chin augmentation
B. Tear trough correction, nose reshaping
C. Midfacial volumization
D. Lip enhancement
E. Hand rejuvenation, and
F. Correction of facial asymmetry.
Dermal Filler Dental Therapeutic Uses
1. Used to establishing aesthetic dental lip lines and smile lines 
as an alternative to crown lengthening, gingivectomy, and 
veneers
2. Treatment of angular cheilitis
3. Elimination of “black triangles” that form between teeth after 
periodontal and implant surgical treatment
4. Re-establishing lip volume for proper phonetics
5. Establishing lip and peri-oral volume around the mouth for 
retention of removable prosthodontics
6. Treatment of a gummy smile.
Conclusion
In recent years, BTX and derma fi llers have made their way 
into dentistry for both dental esthetic and dental therapeutic 
uses in the oral and maxillofacial areas. They are here to stay 
and with more and more intra oral uses of these materials, they 
are fast becoming an integral part of everyday dental practice 
including restorative, aesthetic, periodontal, orthodontic 
and prosthodontics implications. They provide patients with 
most signifi cant, predictable, minimally invasive, aesthetic 
and therapeutic outcomes available for many everyday clinical 
situations.
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